Compare Stocks: ACU, QDEL, CERS, and SMTI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACU Acme United	$61.50 -0.7%	$57.97	$35.50 ▼ $64.17	$234.32M	0.49	22,802 shs	86,997 shs
CERS Cerus	$2.65 -0.4%	$2.72	$1.30 ▼ $3.47	$536.06M	1.8	1.24 million shs	3.57 million shs
QDEL QuidelOrtho	$10.62 -4.2%	$14.85	$9.92 ▼ $35.58	$760.50M	0.68	1.26 million shs	2.98 million shs
SMTI Sanara MedTech	$35.07 +0.3%	$32.21	$16.05 ▼ $35.27	$321.40M	1.16	262,944 shs	271,136 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACU Acme United	-0.71%	+1.28%	+0.72%	+35.52%	+51.07%
CERS Cerus	-0.38%	+6.43%	-7.02%	-1.85%	+115.45%
QDEL QuidelOrtho	-4.24%	-9.85%	-23.04%	-22.31%	-63.04%
SMTI Sanara MedTech	+0.26%	+0.43%	+2.30%	+59.26%	+2.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACU Acme United	$61.50 -0.7%	$57.97	$35.50 ▼ $64.17	$234.32M	0.49	22,802 shs	86,997 shs
CERS Cerus	$2.65 -0.4%	$2.72	$1.30 ▼ $3.47	$536.06M	1.8	1.24 million shs	3.57 million shs
QDEL QuidelOrtho	$10.62 -4.2%	$14.85	$9.92 ▼ $35.58	$760.50M	0.68	1.26 million shs	2.98 million shs
SMTI Sanara MedTech	$35.07 +0.3%	$32.21	$16.05 ▼ $35.27	$321.40M	1.16	262,944 shs	271,136 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACU Acme United	-0.71%	+1.28%	+0.72%	+35.52%	+51.07%
CERS Cerus	-0.38%	+6.43%	-7.02%	-1.85%	+115.45%
QDEL QuidelOrtho	-4.24%	-9.85%	-23.04%	-22.31%	-63.04%
SMTI Sanara MedTech	+0.26%	+0.43%	+2.30%	+59.26%	+2.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACU Acme United	4.00	Strong Buy	N/A	N/A
CERS Cerus	2.40	Hold	$5.25	98.11% Upside
QDEL QuidelOrtho	1.50	Reduce	$13.63	28.30% Upside
SMTI Sanara MedTech	1.80	Reduce	$35.00	-0.20% Downside

Current Analyst Ratings Breakdown

Latest ACU, QDEL, CERS, and SMTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	CERS Cerus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/20/2026	CERS Cerus	Freedom Broker Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.50
8/12/2026	QDEL QuidelOrtho	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/11/2026	SMTI Sanara MedTech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/3/2026	SMTI Sanara MedTech	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/30/2026	SMTI Sanara MedTech	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$35.00
7/30/2026	SMTI Sanara MedTech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$36.00 ➝ $35.00
7/17/2026	QDEL QuidelOrtho	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	SMTI Sanara MedTech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	QDEL QuidelOrtho	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$13.00 ➝ $18.00
7/1/2026	QDEL QuidelOrtho	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underweight	$11.00 ➝ $12.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACU Acme United	$211.60M	1.11	$6.14 per share	10.02	$27.31 per share	2.25
CERS Cerus	$206.13M	2.59	N/A	N/A	$0.34 per share	7.79
QDEL QuidelOrtho	$2.73B	0.27	$18.00 per share	0.59	$28.27 per share	0.38
SMTI Sanara MedTech	$103.12M	3.13	$0.60 per share	58.83	$0.67 per share	52.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACU Acme United	$17.79M	$2.38	12.58	N/A	N/A	10.25%	9.70%	6.10%	N/A
CERS Cerus	-$15.63M	-$0.03	N/A	N/A	N/A	-3.06%	-10.19%	-3.14%	11/5/2026 (Estimated)
QDEL QuidelOrtho	-$1.13B	-$15.41	N/A	7.22	N/A	-39.20%	4.88%	1.63%	11/4/2026 (Estimated)
SMTI Sanara MedTech	-$37.56M	-$3.59	N/A	N/A	N/A	-29.15%	29.72%	2.84%	11/11/2026 (Estimated)

Latest ACU, QDEL, CERS, and SMTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	SMTI Sanara MedTech	-$0.0250	-$0.05	-$0.0250	-$0.05	$28.95 million	$28.14 million
8/6/2026	Q2 2026	QDEL QuidelOrtho	-$0.0488	$0.13	+$0.1788	-$1.36	$618.72 million	$630.90 million
7/30/2026	Q2 2026	CERS Cerus	-$0.0133	-$0.01	+$0.0033	-$0.01	$62.90 million	$63.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACU Acme United	$0.64	1.04%	+5.25%	26.89%	20 Years
CERS Cerus	N/A	N/A	N/A	N/A	N/A
QDEL QuidelOrtho	N/A	N/A	N/A	N/A	N/A
SMTI Sanara MedTech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACU Acme United	0.30	4.41	1.91
CERS Cerus	0.49	1.83	1.07
QDEL QuidelOrtho	1.43	1.39	0.76
SMTI Sanara MedTech	5.86	2.58	2.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACU Acme United	62.10%
CERS Cerus	78.37%
QDEL QuidelOrtho	99.00%
SMTI Sanara MedTech	8.10%

Insider Ownership

Company	Insider Ownership
ACU Acme United	29.50%
CERS Cerus	5.30%
QDEL QuidelOrtho	1.10%
SMTI Sanara MedTech	42.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACU Acme United	649	3.81 million	2.50 million	Not Optionable
CERS Cerus	345	201.52 million	190.84 million	Optionable
QDEL QuidelOrtho	6,500	68.57 million	67.82 million	Optionable
SMTI Sanara MedTech	108	9.19 million	5.33 million	Not Optionable

ACU, QDEL, CERS, and SMTI Headlines

Recent News About These Companies

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

September 10, 2026 | businesswire.com

BlackRock Inc. Takes $5.87 Million Position in Sanara MedTech Inc. $SMTI

September 6, 2026 | marketbeat.com

Sanara MedTech Inc. (NASDAQ:SMTI) Given Average Recommendation of "Reduce" by Analysts

September 1, 2026 | marketbeat.com

SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders

August 29, 2026 | businesswire.com

Sanara MedTech Inc

August 14, 2026 | money.usnews.com

Sanara MedTech Inc. (SMTI) Tops Q2 Earnings Estimates

August 11, 2026 | zacks.com

Sanara MedTech Inc. (SMTI) Releases Q2 2026 Earnings: Revenue Rises 8.9%

August 11, 2026 | quiverquant.comQ

Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)

August 11, 2026 | globenewswire.com

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—FBRX, LXFR, SMTI, and MKTX

August 6, 2026 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—FBRX, LXFR, SMTI, and MKTX

August 4, 2026 | globenewswire.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ), Sanara MedTech Inc. (Nasdaq – SMTI), TriCo Bancshares (Nasdaq – TCBK)

August 4, 2026 | globenewswire.com

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

August 3, 2026 | businesswire.com

MiMedx to acquire Sanara MedTech for $350M

July 31, 2026 | massdevice.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sanara MedTech Inc. (NASDAQ: SMTI)

July 30, 2026 | prnewswire.com

July 30, 2026 | globenewswire.com

Shareholder Alert: Ademi LLP investigates whether Sanara MedTech Inc. is obtaining a Fair Price for Public Shareholders

July 30, 2026 | prnewswire.com

SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders

July 30, 2026 | aol.comA

MiMedx agrees to buy Sanara MedTech for $35 a share

July 30, 2026 | msn.com

Sanara MedTech agrees to be acquired by MiMedx

July 29, 2026 | tipranks.com

MIMEDX to Acquire Sanara MedTech

July 29, 2026 | globenewswire.com

Sanara MedTech (SMTI) Stock Gets Fair Value Bump As Analysts Back Wound Care Growth

June 23, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACU, QDEL, CERS, and SMTI Company Descriptions

Acme United NYSE:ACU

$61.50 -0.44 (-0.71%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$61.50 +0.01 (+0.01%)

As of 09/18/2026 07:30 PM Eastern

Acme United Corporation supplies cutting, measuring, first aid, and sharpening products to the school, home, office, hardware, sporting goods, and industrial markets in the United States, Canada, Europe, and internationally. The company offers scissors, shears, knives, rulers, pencil sharpeners, paper trimmers, safety cutters, lettering products, glue guns, and other craft products under the Westcott brand name; and cutting tools under the Clauss brand. It also provides sharpening knives, scissors, chisels, skis, skates, and other edge under the DMT brand. In addition, the company offers first aid kit and safety solutions under the First Aid Only brand; portable eyewash solution and over-the-counter medication, including active ingredients aspirin, acetaminophen, and ibuprofen under the PhysiciansCare brand; bodily fluid and spill clean-up solution under the Spill Magic brand; various first aid kit, refill, and safety supplies, including CPR kits, burn kits, and automotive and emergency first aid kits under the First Aid Central; first aid kits for the promotional products industry under Safety Made brand; and alcohol prep pads, alcohol wipes, benzalkonium chloride wipes, various antiseptic wipes, castile soaps, and lens cleaning wipes under the Med-Nap brand. It sells its products directly and through its independent manufacturer representatives to wholesale, contract, and retail stationery distributors; office supply super stores, mass market retailers, industrial and medical distributors, school supply distributors, drug store retailers, sporting goods stores, hardware chains, and wholesale florists, as well as through its websites. The company was formerly known as Acme Shear Company and changed its name to Acme United Corporation in 1971. Acme United Corporation was founded in 1867 and is based in Shelton, Connecticut.

Cerus NASDAQ:CERS

$2.65 -0.01 (-0.38%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.69 +0.04 (+1.43%)

As of 09/18/2026 07:55 PM Eastern

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

QuidelOrtho NASDAQ:QDEL

$10.62 -0.47 (-4.24%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.61 -0.01 (-0.13%)

As of 09/18/2026 07:51 PM Eastern

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Sanara MedTech NASDAQ:SMTI

$35.07 +0.09 (+0.26%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$35.06 -0.01 (-0.03%)

As of 09/18/2026 07:30 PM Eastern

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACU, QDEL, CERS, and SMTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACU, QDEL, CERS, and SMTI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACU, QDEL, CERS, and SMTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACU, QDEL, CERS, and SMTI Company Descriptions

Acme United NYSE:ACU

Cerus NASDAQ:CERS

QuidelOrtho NASDAQ:QDEL

Sanara MedTech NASDAQ:SMTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACU, QDEL, CERS, and SMTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACU, QDEL, CERS, and SMTI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACU, QDEL, CERS, and SMTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ACU, QDEL, CERS, and SMTI Company Descriptions

Acme United NYSE:ACU

Cerus NASDAQ:CERS

QuidelOrtho NASDAQ:QDEL

Sanara MedTech NASDAQ:SMTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools